A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophyNathalie Goemans, Yasuhiro Takeshima, Eugenio Mercuri et al.|Neuromuscular Disorders|2017Cited by 128
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trialCraig M. McDonald, Laura Brown, Nathaniel Hogan et al.|The Lancet|2026Cited by 0